Incannex Healthcare (IXHL) Expected to Announce Earnings on Friday

Incannex Healthcare (NASDAQ:IXHL) is expected to be releasing its Q2 2026 results before the market opens on Friday, February 13th. Analysts expect Incannex Healthcare to post earnings of ($0.02) per share for the quarter. Parties can find conference call details on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Friday, February 20, 2026 at 12:30 PM ET.

Incannex Healthcare (NASDAQ:IXHL) last issued its quarterly earnings data on Friday, November 14th. The company reported ($0.02) earnings per share for the quarter, beating the consensus estimate of ($0.39) by $0.37. The company had revenue of $0.05 million during the quarter, compared to the consensus estimate of $0.20 million.

Incannex Healthcare Stock Performance

Shares of IXHL stock opened at $0.28 on Wednesday. Incannex Healthcare has a 52 week low of $0.08 and a 52 week high of $1.95. The company has a market capitalization of $97.64 million, a price-to-earnings ratio of -0.48 and a beta of 7.46. The company has a 50-day simple moving average of $0.37 and a 200 day simple moving average of $0.43.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Incannex Healthcare stock. Virtu Financial LLC purchased a new stake in Incannex Healthcare Inc. (NASDAQ:IXHL) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 402,443 shares of the company’s stock, valued at approximately $187,000. Virtu Financial LLC owned approximately 0.12% of Incannex Healthcare at the end of the most recent quarter. Institutional investors and hedge funds own 0.43% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Incannex Healthcare in a report on Thursday, January 22nd. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Incannex Healthcare currently has a consensus rating of “Sell”.

About Incannex Healthcare

Incannex Healthcare Ltd is a clinical-stage biopharmaceutical company focused on developing novel therapies that combine cannabinoid and psychedelic compounds. Headquartered in Melbourne, Australia, with research operations in the United States, the company seeks to leverage the therapeutic potential of its proprietary formulations to address a range of medical conditions. Incannex is publicly traded on the NASDAQ under the ticker IXHL and maintains a presence in both Australia and North America.

The company’s research and development pipeline includes multiple product candidates in various stages of clinical evaluation.